Sartorius Group
First-Half Financial Report
2021
“In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug development so that innovative therapies reach patients faster.
Due to the ongoing expansion of our production facilities worldwide, we are well prepared to respond to the high demand expected to continue, and recruitment of additional employees is continuing at full speed. As communicated at the beginning of July, we significantly raised our sales and earnings forecast for the full year yet again though forecasts are currently subject to above-average uncertainty due to the various pandemic-related effects.”
Joachim Kreuzburg
CEO and Executive Board Chairman
Sales revenue
€1,629.2m
in constant FX +60.1%
Underlying EBITDA
€555.3m
+89.2%
Order intake
€2,178.8m
in constant FX +82.4%
Employees
11,981
+23.1%
Market capitalization
~€29.5bn
+60.6%
Group Business Development and Divisions
Sartorius has continued on its fast growth trajectory begun at the start of the year, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake. The majority of this growth was generated through the organic expansion by both divisions in all regions and is based on unabated high demand for innovative technologies used in the development and production of biopharmaceuticals, both in the area of classic monoclonal antibodies and in the emerging fields of cell and gene therapies. In addition to solid performance by this core business, Sartorius benefited to a certain extent also from additional demand related to the manufacture of coronavirus vaccines and coronavirus test kits.